Oxford Immunotec to supply T cell testing for UK COVID-19 vaccine trials

By Rachel Arthur

- Last updated on GMT


Related tags T cell COVID-19 vaccine Uk

Diagnostics company Oxford Immunotec Global PLC has been selected to provide T cell testing to the UK Vaccines Taskforce.

T cells are becoming increasingly recognised for their role in SARS-CoV-2 infection and immunity; measuring the presence and size of any T cell response can give adjunctive information to that available by serology. The UK Vaccines Taskforce therefore is including T cell analysis in COVID-19 vaccine trials.

Oxford Immunotec – which is based in Oxford, UK and Marlborough, Massachusetts - will be the sole supplier of T cell testing for SARS-CoV-2 specific responses in the UK’s COVID-19 vaccine trials.

Its T-SPOT technology has been in operation for 15 years in the field of tuberculosis diagnosis. It will now offer the UK Vaccines Task Force its T-SPOT Discovery​ SARS-CoV-2 assay (research use only): which uses the same technology to allow SARS-CoV-2-specific T cells to be detected and enumerated. 

The award includes the measurement of the magnitude of the SARS-CoV-2 protein-specific T cell response using T-SPOT Discovery​ and is ‘recognition of the company’s ability to deliver clinical grade, consistent and reproducible diagnostic products.’

The UK Government will provide up to £3m ($3.9m) investment for this testing.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more